{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T20:15:42Z","timestamp":1771964142324,"version":"3.50.1"},"reference-count":42,"publisher":"Jaypee Brothers Medical Publishing","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.59556\/japi.72.0622","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T09:22:25Z","timestamp":1752225745000},"page":"64-72","source":"Crossref","is-referenced-by-count":1,"title":["LIpid Response to Statins \u00b1 Ezetimibe In Mumbai (LIRIM): A Cross-sectional Observational Study"],"prefix":"10.59556","volume":"72","author":[{"given":"Shah","family":"VT","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20250711092220_B1","unstructured":"Cardiovascular diseases (CVDs) [Internet]. [cited 2023 Jul 28]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"key20250711092220_B2","unstructured":"Cardiovascular diseases [Internet]. [cited 2023 Jul 28]. Available from: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases"},{"key":"key20250711092220_B3","unstructured":"India | The Institute for Health Metrics and Evaluation [Internet]. [cited 2023 Jul 28]. Available from: https:\/\/www.healthdata.org\/research-analysis\/health-by-location\/profiles\/india"},{"issue":"(1):","key":"key20250711092220_B4","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.1016\/j.mjafi.2019.12.005","article-title":"Cardiovascular disease in India: A 360 degree overview.","volume":"76","author":"Sreeniwas Kumar","year":"2020;","journal-title":"Med J Armed Forces India"},{"issue":"(2):","key":"key20250711092220_B5","doi-asserted-by":"crossref","first-page":"e1\u2013","DOI":"10.1016\/j.jacl.2020.01.006","article-title":"Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.","volume":"14","author":"Puri","year":"2020;","journal-title":"J Clin Lipidol"},{"issue":"(1):","key":"key20250711092220_B6","doi-asserted-by":"crossref","first-page":"111\u2013","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020;","journal-title":"Eur Heart J"},{"issue":"(11):","key":"key20250711092220_B7","first-page":"e596\u2013","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019;","journal-title":"Circulation"},{"issue":"(25):","key":"key20250711092220_B8","first-page":"e1082\u2013","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019;","journal-title":"Circulation"},{"issue":"(34):","key":"key20250711092220_B9","doi-asserted-by":"crossref","first-page":"3227\u2013","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021;","journal-title":"Eur Heart J"},{"issue":"(11):","key":"key20250711092220_B10","doi-asserted-by":"crossref","first-page":"2220\u2013","DOI":"10.1161\/ATVBAHA.116.307601","article-title":"Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events.","volume":"36","author":"Puri","year":"2016;","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"(2):","key":"key20250711092220_B11","first-page":"160\u2013","article-title":"Non-HDL cholesterol as a metric of good quality of care.","volume":"38","author":"Virani","year":"2011;","journal-title":"Tex Heart Inst J"},{"issue":"(1):","key":"key20250711092220_B12","doi-asserted-by":"crossref","first-page":"289\u2013","DOI":"10.1016\/j.atherosclerosis.2008.03.014","article-title":"Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals.","volume":"202","author":"Orakzai","year":"2009;","journal-title":"Atherosclerosis"},{"key":"key20250711092220_B13","doi-asserted-by":"crossref","first-page":"230\u2013","DOI":"10.1016\/j.atherosclerosis.2018.05.010","article-title":"Non-HDL-C levels and residual cardiovascular risk: Do population-specific precision approaches offer any advantages?","volume":"274:","author":"Enkhmaa","year":"2018;","journal-title":"Atherosclerosis"},{"issue":"(Suppl 3):","key":"key20250711092220_B14","first-page":"19\u2013","article-title":"New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines.","volume":"26","author":"Brewer","year":"2007;","journal-title":"Clin Cardiol"},{"issue":"(1):","key":"key20250711092220_B15","doi-asserted-by":"crossref","first-page":"66.","DOI":"10.1001\/jamacardio.2016.4709","article-title":"Statins\u2014almost 30 years of use in the United States and still not quite there.","volume":"2","author":"Harrington","year":"2017;","journal-title":"JAMA Cardiol"},{"key":"key20250711092220_B16","unstructured":"Use of statins in India: a survey to understand the prescribing patterns of physicians in India- score study | International Journal of Current Research [Internet]. [cited 2023 Aug 23]. Available from: https:\/\/www.journalcra.com\/article\/use-statins-india-survey-understand-prescribing-patterns-physicians-india-score-study"},{"key":"key20250711092220_B17","doi-asserted-by":"crossref","first-page":"212534.","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications.","volume":"7:","author":"Vavlukis","year":"2018;","journal-title":"Drugs Context"},{"key":"key20250711092220_B18","doi-asserted-by":"crossref","first-page":"53\u2013","DOI":"10.1016\/j.atherosclerosis.2023.06.003","article-title":"High cholesterol absorption: a risk factor of atherosclerotic cardiovascular diseases?","volume":"376:","author":"Simonen","year":"2023;","journal-title":"Atherosclerosis"},{"issue":"(1):","key":"key20250711092220_B19","doi-asserted-by":"crossref","first-page":"19\u2013","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin.","volume":"24","author":"Naito","year":"2017;","journal-title":"J Atheroscler Thromb"},{"key":"key20250711092220_B20","doi-asserted-by":"crossref","first-page":"24\u2013","DOI":"10.2174\/1874192401105010024","article-title":"Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.","volume":"5:","author":"Athyros","year":"2011;","journal-title":"Open Cardiovasc Med J"},{"issue":"(9):","key":"key20250711092220_B21","doi-asserted-by":"crossref","first-page":"67\u2013","DOI":"10.5005\/japi-11001-0099","article-title":"Unmet need for further LDL-C lowering in India despite statin therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.","volume":"70","author":"Mehta","year":"2022;","journal-title":"J Assoc Physicians India"},{"issue":"(15):","key":"key20250711092220_B22","doi-asserted-by":"crossref","first-page":"1571\u2013","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).","volume":"137","author":"Giugliano","year":"2018;","journal-title":"Circulation"},{"issue":"(21):","key":"key20250711092220_B23","first-page":"e984\u2013","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association.","volume":"143","author":"Powell-Wiley","year":"2021;","journal-title":"Circulation"},{"issue":"(4):","key":"key20250711092220_B24","doi-asserted-by":"crossref","first-page":"1218\u2013","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: mechanisms and potential targets.","volume":"5","author":"Klop","year":"2013;","journal-title":"Nutrients"},{"key":"key20250711092220_B25","doi-asserted-by":"crossref","first-page":"71\u2013","DOI":"10.1016\/j.metabol.2018.11.005","article-title":"Obesity and dyslipidemia.","volume":"92:","author":"Vekic","year":"2019;","journal-title":"Metabolism"},{"issue":"(7):","key":"key20250711092220_B26","doi-asserted-by":"crossref","first-page":"575\u2013","DOI":"10.1080\/14779072.2021.1940959","article-title":"Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia.","volume":"19","author":"Boutari","year":"2021;","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"key20250711092220_B27","doi-asserted-by":"crossref","first-page":"789931.","DOI":"10.3389\/fcvm.2021.789931","article-title":"Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol.","volume":"8:","author":"Bardolia","year":"2021;","journal-title":"Front Cardiovasc Med"},{"key":"key20250711092220_B28","doi-asserted-by":"crossref","first-page":"122\u2013","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial.","volume":"320:","author":"Rubino","year":"2021;","journal-title":"Atherosclerosis"},{"issue":"(1):","key":"key20250711092220_B29","doi-asserted-by":"crossref","first-page":"24\u2013","DOI":"10.4244\/AIJ-D-22-00005","article-title":"Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how: aggressive lipid-lowering therapy after PCI.","volume":"8","author":"Lee","year":"2022;","journal-title":"AsiaIntervention"},{"key":"key20250711092220_B30","doi-asserted-by":"crossref","first-page":"8129513.","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-a narrative review.","volume":"2022:","author":"Mer\u0107ep","year":"2022;","journal-title":"Cardiovasc Ther"},{"issue":"(5):","key":"key20250711092220_B31","doi-asserted-by":"crossref","first-page":"673\u2013","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).","volume":"99","author":"Ballantyne","year":"2007;","journal-title":"Am J Cardiol"},{"issue":"(2):","key":"key20250711092220_B32","doi-asserted-by":"crossref","first-page":"226\u2013","DOI":"10.1016\/j.clinthera.2017.12.018","article-title":"A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial.","volume":"40","author":"Hong","year":"2018;","journal-title":"Clin Ther"},{"issue":"(11):","key":"key20250711092220_B33","doi-asserted-by":"crossref","first-page":"1622\u2013","DOI":"10.5551\/jat.63940","article-title":"Achievement rates for low-density lipoprotein cholesterol goals in patients at high risk of atherosclerotic cardiovascular disease in a real-world setting in Japan.","volume":"30","author":"Mitani","year":"2023;","journal-title":"J Atheroscler Thromb"},{"issue":"(11):","key":"key20250711092220_B34","doi-asserted-by":"crossref","first-page":"1279\u2013","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.","volume":"28","author":"Ray","year":"2021;","journal-title":"Eur J Prev Cardiol"},{"issue":"(9):","key":"key20250711092220_B35","doi-asserted-by":"crossref","first-page":"3187.","DOI":"10.3390\/jcm12093187","article-title":"Real-world attainment of low-density lipoprotein cholesterol goals in patients at high risk of cardiovascular disease treated with high-intensity statins: the TERESA study.","volume":"12","author":"Barrios","year":"2023;","journal-title":"J Clin Med"},{"issue":"(5):","key":"key20250711092220_B36","doi-asserted-by":"crossref","first-page":"640\u2013","DOI":"10.1177\/0897190019825915","article-title":"Real-world effectiveness of high- versus moderate-intensity statin therapy in thai patients with acute coronary syndrome and who had undergone primary percutaneous coronary intervention.","volume":"33","author":"Kunlamas","year":"2020;","journal-title":"J Pharm Pract"},{"issue":"(6):","key":"key20250711092220_B37","doi-asserted-by":"crossref","first-page":"766\u2013","DOI":"10.1016\/j.ihj.2016.09.002","article-title":"Efficacy and safety of the intensive dose of rosuvastatin 40mg\/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.","volume":"68","author":"Shah","year":"2016;","journal-title":"Indian Heart J"},{"issue":"(11):","key":"key20250711092220_B38","first-page":"e31468.","article-title":"Real-world clinical experience of rosuvastatin as a lipid-lowering therapy for primary and secondary prevention of cardiovascular events (REAL ROSE).","volume":"14","author":"Mehta","year":"2022;","journal-title":"Cureus"},{"key":"key20250711092220_B39","doi-asserted-by":"crossref","first-page":"2177\u2013","DOI":"10.2147\/DDDT.S332352","article-title":"Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights.","volume":"16:","author":"Chilbert","year":"2022;","journal-title":"Drug Des Devel Ther"},{"key":"key20250711092220_B40","doi-asserted-by":"crossref","first-page":"137.","DOI":"10.1186\/1476-511X-12-137","article-title":"Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.","volume":"12:","author":"Torimoto","year":"2013;","journal-title":"Lipids Health Dis"},{"issue":"(5):","key":"key20250711092220_B41","doi-asserted-by":"crossref","first-page":"371\u2013","DOI":"10.1111\/1755-5922.12213","article-title":"Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).","volume":"34","author":"Kim","year":"2016;","journal-title":"Cardiovasc Ther"},{"issue":"(4):","key":"key20250711092220_B42","doi-asserted-by":"crossref","first-page":"859\u2013","DOI":"10.1007\/s13300-020-00778-1","article-title":"Comparison of the efficacy and safety of rosuvastatin\/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study.","volume":"11","author":"Lee","year":"2020;","journal-title":"Diabetes Ther"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T09:22:32Z","timestamp":1752225752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-9-64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.59556\/japi.72.0622"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0622","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}